Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Posaconazole

Posaconazole Reactions 1704, p311 - 2 Jun 2018 Development of posaconazole cross-resistance in invasive pulmonary aspergillosis: case report A patient [age and sex not stated] developed development of posaconazole cross-resistance in invasive pulmonary aspergillosis (IPA) during treatment with posaconazole [route, dosage, time to reaction onset not stated]. The patient, who had been receiving posaconazole prophylaxis for prolonged time due to chronic graft-versus-host disease, showed posaconazole cross-resistance. The MIC data showed itraconazole resistant IPA. Author comment: "Posaconazole cross-resistance in patients with prolonged use of posaconazole prophylaxis due to chronic graft-versus-host diseases"."Antifungal resistance was not common, but possible". Cho SY, et al. Identification using panfungal PCR and susceptibility testing for Aspergillus clinical isolates from hematologic patients with invasive pulmonary aspergillosis. International Journal of Antimicrobial Agents 50 (Suppl. 1): S119, Sep 2017 [abstract] - South Korea 803323818 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Posaconazole

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Posaconazole

Abstract

Reactions 1704, p311 - 2 Jun 2018 Development of posaconazole cross-resistance in invasive pulmonary aspergillosis: case report A patient [age and sex not stated] developed development of posaconazole cross-resistance in invasive pulmonary aspergillosis (IPA) during treatment with posaconazole [route, dosage, time to reaction onset not stated]. The patient, who had been receiving posaconazole prophylaxis for prolonged time due to chronic graft-versus-host disease, showed posaconazole...
Loading next page...
 
/lp/springer_journal/posaconazole-fyTkflbyZV
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46954-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p311 - 2 Jun 2018 Development of posaconazole cross-resistance in invasive pulmonary aspergillosis: case report A patient [age and sex not stated] developed development of posaconazole cross-resistance in invasive pulmonary aspergillosis (IPA) during treatment with posaconazole [route, dosage, time to reaction onset not stated]. The patient, who had been receiving posaconazole prophylaxis for prolonged time due to chronic graft-versus-host disease, showed posaconazole cross-resistance. The MIC data showed itraconazole resistant IPA. Author comment: "Posaconazole cross-resistance in patients with prolonged use of posaconazole prophylaxis due to chronic graft-versus-host diseases"."Antifungal resistance was not common, but possible". Cho SY, et al. Identification using panfungal PCR and susceptibility testing for Aspergillus clinical isolates from hematologic patients with invasive pulmonary aspergillosis. International Journal of Antimicrobial Agents 50 (Suppl. 1): S119, Sep 2017 [abstract] - South Korea 803323818 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References